Aktuellt
SENASTE
Redeye comments on Spago’s Q4 2021 report, coming at an exciting time for the company with both the SpagoPix and Tumorad projects progressing in the right direction. Looking forward, we believe top-line data for the company’s ongoing SPAGOPIX-01 study and a potential licensing deal for SpagoPix during 2022 will act as the main catalysts for Spago’s share. Further, Tumorad entering clinical development will diversify the company’s clinical pipeline and increase Spago’s potential. We make minor changes to our anticipated timelines and increase our discount rate given a perceived slightly increased financing risk.
LÄS MER
